Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

Yu-Tao Liu,1 Xue-Zhi Hao,1 De-Ruo Liu,2 Gang Cheng,3 Shu-Cai Zhang,4 Wen-Hua Xiao,5 Yi Hu,6 Jun-Feng Liu,7 Ming He,7 Cui-Min Ding,8 Li Zhang,9 Jun Wang,10 Hui Li,11 Gui-Lan Dong,12 Xiu-Yi Zhi,13 Jian Li,14 Yuan-Kai Shi1 1Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Ant...

Full description

Bibliographic Details
Main Authors: Liu YT, Hao XZ, Liu DR, Cheng G, Zhang SC, Xiao WH, Hu Y, Liu JF, He M, Ding CM, Zhang L, Wang J, Li H, Dong GL, Zhi XY, Li J, Shi YK
Format: Article
Language:English
Published: Dove Medical Press 2020-06-01
Series:Cancer Management and Research
Subjects:
efgr mutation
non-small-cell lung cancer (nsclc)
lung adenocarcinoma
icotinib
adjuvant chemotherapy
Online Access:https://www.dovepress.com/icotinib-as-adjuvant-treatment-for-stage-ii-iiia-lung-adenocarcinoma-p-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/icotinib-as-adjuvant-treatment-for-stage-ii-iiia-lung-adenocarcinoma-p-peer-reviewed-article-CMAR

Similar Items